Search results for "CD4-Positive T-Lymphocyte"

showing 10 items of 254 documents

MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.

2003

The ability to activate CD4 T cells is restricted to antigen-presenting cells that express major histocompatibility complex (MHC) class II molecules. Parenchymal cells normally do not express MHC class II molecules; however, in clinical hepatitis, viral or autoimmune, hepatocytes often exhibit aberrant MHC class II expression. It is not known whether MHC class II-expressing hepatocytes can function as antigen-presenting cells, but it has been suggested that aberrant MHC class II expression by parenchymal cells may cause autoimmune disease. Therefore, we generated transgenic mice that specifically overexpress class II transactivator molecules in hepatocytes. Hepatocytes from these mice exhib…

CD4-Positive T-LymphocytesCD74Antigen presentationCD1Antigen-Presenting CellsGene ExpressionMice Inbred StrainsMice TransgenicLymphocyte ActivationHepatitisMiceMHC class ICytotoxic T cellAnimalsMHC class IIHepatologybiologyAntigen processingHistocompatibility Antigens Class IINuclear ProteinsMHC restrictionCell biologyImmunologybiology.proteinHepatocytesTrans-ActivatorsHepatology (Baltimore, Md.)
researchProduct

A Key Regulatory Role of the Transcription Factor NFATc2 in Bronchial Adenocarcinoma via CD8+ T Lymphocytes

2009

AbstractThe Ca2+-regulated calcineurin/nuclear factor of activated T cells (NFAT) cascade controls alternative pathways of T-cell activation and peripheral tolerance. Here, we describe reduction of NFATc2 mRNA expression in the lungs of patients with bronchial adenocarcinoma. In a murine model of bronchoalveolar adenocarcinoma, mice lacking NFATc2 developed more and larger solid tumors than wild-type littermates. The extent of central tumor necrosis was decreased in the tumors in NFATc2(−/−) mice, and this finding was associated with reduced tumor necrosis factor-α and interleukin-2 (IL-2) production by CD8+ T cells. Adoptive transfer of CD8+ T cells of NFATc2(−/−) mice induced transforming…

CD4-Positive T-LymphocytesCancer ResearchAdoptive cell transferTranscription GeneticTransplantation HeterologousMice TransgenicReceptors Nerve Growth FactorAdenocarcinomaCD8-Positive T-LymphocytesBiologyReceptors Tumor Necrosis FactorTransforming Growth Factor beta1Interferon-gammaMiceGlucocorticoid-Induced TNFR-Related ProteinAnimalsHumansIL-2 receptorInterleukin-7 receptorMice Inbred BALB CReceptors Interleukin-7NFATC Transcription FactorsTumor Necrosis Factor-alphaBronchial NeoplasmsInterleukin-2 Receptor alpha SubunitPeripheral toleranceForkhead Transcription FactorsNFATCalcineurinDisease Models AnimalOncologyCancer researchInterleukin-2Tumor necrosis factor alphaCD8Cancer Research
researchProduct

SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth.

2013

Abstract Activation of the transcription factor PPARγ by the n-3 fatty acid docosahexaenoic acid (DHA) is implicated in controlling proinflammatory cytokine secretion, but the intracellular signaling pathways engaged by PPARγ are incompletely characterized. Here, we identify the adapter-encoding gene SOCS3 as a critical transcriptional target of PPARγ. SOCS3 promoter binding and gene transactivation by PPARγ was associated with a repression in differentiation of proinflammatory T-helper (TH)17 cells. Accordingly, TH17 cells induced in vitro displayed increased SOCS3 expression and diminished capacity to produce interleukin (IL)-17 following activation of PPARγ by DHA. Furthermore, naïve CD4…

CD4-Positive T-LymphocytesCancer ResearchAngiogenesisMammary Neoplasms Experimental/genetics/pathology/prevention & controlSuppressor of Cytokine Signaling Proteinsddc:616.07BioinformaticsTransactivationMice0302 clinical medicineTumor Burden/drug effects/geneticsSOCS3Docosahexaenoic Acids/administration & dosage/pharmacologyPromoter Regions GeneticMice Knockout0303 health sciencesMice Inbred BALB CChemistryReverse Transcriptase Polymerase Chain ReactionInterleukin-17InterleukinCell DifferentiationCell biologyTumor BurdenOncology030220 oncology & carcinogenesisFemaleRNA InterferenceInterleukin 17Th17 Cells/drug effects/metabolismTranscriptional ActivationDocosahexaenoic AcidsBlotting WesternMice NudeCD4-Positive T-Lymphocytes/drug effects/metabolismProinflammatory cytokine03 medical and health sciencesSuppressor of Cytokine Signaling Proteins/genetics/metabolismCell Line TumorAnimalsTranscription factor030304 developmental biologyMammary Neoplasms ExperimentalPromoter Regions Genetic/geneticsDietMice Inbred C57BLPPAR gammaInterleukin-17/metabolismCell cultureSuppressor of Cytokine Signaling 3 ProteinCell Differentiation/drug effectsPPAR gamma/agonists/genetics/metabolismTh17 CellsCancer research
researchProduct

CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes

2013

CD39 is an ectoenzyme, present on different immune cell subsets, which mediates immunosuppressive functions catalyzing ATP degradation. It is not known whether CD39 is expressed and implicated in the activity of CD8+ regulatory T lymphocytes (Treg). In this study, CD39 expression and function was analyzed in both CD8+ and CD4+CD25hi Treg from the peripheral blood of healthy donors as well as from tumor specimens. CD39 was found expressed by both CD8+ (from the majority of healthy donors and tumor patients) and CD4+CD25 hi Treg, and CD39 expression correlated with suppression activity mediated by CD8+ Treg. Importantly, CD39 counteraction remarkably inhibited the suppression activity of CD8+…

CD4-Positive T-LymphocytesCancer ResearchImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyT-Lymphocytes RegulatoryImmune toleranceAntineoplastic AgentLymphocytes Tumor-InfiltratingImmune systemAntigenAntigens CDImmune TolerancemedicineHumansIndoleamine-Pyrrole 23-DioxygenaseImmunology and AllergyCell ProliferationCD39Tumor microenvironmentCell growthApyraseInterleukin-2 Receptor alpha SubunitCD8-Positive T-LymphocyteTumor immune escapePhenotypePhenotypeCD39 CD8+ Treg Tumor immune escape ToleranceMicroscopy FluorescenceOncologyMechanism of actionCD4-Positive T-LymphocyteImmunologyCD8+ Tregmedicine.symptomToleranceCD8HumanCancer Immunology, Immunotherapy
researchProduct

MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4

2015

A body of experimental evidence suggests that T cells mediate neuroprotection following CNS injury; however, the antigen specificity of these T cells and how they mediate neuroprotection are unknown. Here, we have provided evidence that T cell-mediated neuroprotection after CNS injury can occur independently of major histocompatibility class II (MHCII) signaling to T cell receptors (TCRs). Using two murine models of CNS injury, we determined that damage-associated molecular mediators that originate from injured CNS tissue induce a population of neuroprotective, IL-4-producing T cells in an antigen-independent fashion. Compared with wild-type mice, IL-4-deficient animals had decreased functi…

CD4-Positive T-LymphocytesCancer ResearchMAP Kinase Signaling SystemPopulationReceptors Antigen T-CellInflammationBiologyNeuroprotectionMiceAntigenClinical investigationAnimalsMedicineExtracellular Signal-Regulated MAP KinaseseducationReceptorInterleukin 4Mice Knockouteducation.field_of_studybusiness.industryT-cell receptorHistocompatibility Antigens Class IINeurodegenerative DiseasesGeneral MedicineAxonsCell biologyBrain InjuriesMyeloid Differentiation Factor 88Immunologybiology.proteinInterleukin-4medicine.symptomFunction and Dysfunction of the Nervous SystemCorrigendumbusinessProto-Oncogene Proteins c-aktResearch ArticleNeurotrophinJournal of Clinical Investigation
researchProduct

Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma…

1997

Tumor-reactive CD4+ T cells have been isolated from tumor patients, and their specifity but not T-cell receptor (TCR) repertoire has been analyzed. Since we have described CD4+ sarcoma-reactive T-cell clones, we now sought to determine whether the TCR repertoire of these clones provides information on the spectrum of recognized sarcoma antigens. We analyzed the TCR beta (TCRB) chain repertoire of 19 CD4+ HLA-DR-restricted T-cell clones reactive with the autologous sarcoma cell line MZ-MES-1, with HLA-DR-matched tumor cell lines of different tissue origins and B-cell blasts. We identified 7 different clonotypes, which used a limited set of TCRBV and TCRBJ segments. Although the CDR3 of the d…

CD4-Positive T-LymphocytesCancer ResearchReceptors Antigen T-Cell alpha-betaLymphocyteBiologyPolymerase Chain ReactionInterferon-gammaImmune systemAntigenAntigens NeoplasmStomach NeoplasmsTumor Cells CulturedHLA-DRmedicineHumansMelanomaPan-T antigensT-cell receptorSarcomaHLA-DR AntigensT lymphocyteFetal BloodJunctional diversityClone Cellsmedicine.anatomical_structureOncologyImmunologyInternational Journal of Cancer
researchProduct

The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into funct…

2000

Abstract Objective . Hyper-IL-6, a fusion protein of interleukin-6 and its specific receptor, together with stem cell factor leads to the proliferation of primitive hematopoietic progenitor cells. Based on these findings, the current study examined whether hyper-IL-6 promotes the growth of precursor cells that can be further differentiated into dendritic cells in the presence of additional cytokines. Methods . Dendritic cell cultures were generated from CD34 + hematopoietic progenitor cells derived either from bone marrow or from peripheral blood. CD34 + cells were cultured in the presence of cytokines for 2 weeks and then used for phenotyping and T-cell stimulation assays. Results . Hyper-…

CD4-Positive T-LymphocytesCancer ResearchRecombinant Fusion ProteinsAntigen presentationBiologyDinoprostoneImmunophenotypingAntigens CDOxytocicsGeneticsCytokine Receptor gp130HumansProgenitor cellAntigen-presenting cellMolecular BiologyCells CulturedInterleukin 3Antigen PresentationStem Cell FactorMembrane GlycoproteinsFollicular dendritic cellsInterleukin-6Tumor Necrosis Factor-alphaGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyHematologyDendritic cellDendritic CellsReceptors InterleukinFlow CytometryHematopoietic Stem CellsHepatitis B Core AntigensReceptors Interleukin-6Recombinant ProteinsCell biologyEndothelial stem cellMyeloid-derived Suppressor CellInterleukin-4Cell DivisionInterleukin-1Experimental hematology
researchProduct

Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer

2015

Abstract CD4 T cells are key components of the immune system that shape the anticancer immune response in animal models and in humans. The biology of CD4 T cells is complex because naïve T cells can differentiate into various subpopulations with various functions. Recently, a new population called Th9 cells was described. These cells are characterized by their ability to produce IL9 and IL21. They were first described in the context of parasite infections and allergic processes. However, some reports described their presence in the tumor bed in mice and humans. Their high secretion of IL9 and IL21 in the tumor bed contributes to their anticancer functions. Indeed, these cytokines trigger th…

CD4-Positive T-LymphocytesCancer ResearchTranscription GeneticT-LymphocytesAntigen presentationCD8-Positive T-LymphocytesBiologyMiceImmune systemNeoplasmsAnimalsHumansCytotoxic T cellAntigen-presenting cellGene Expression ProfilingInterleukinsInterleukin-9LymphokineCell DifferentiationT-Lymphocytes Helper-InducerNatural killer T cellAcquired immune systemOncologyImmunologyInterleukin 12Cancer researchCancer Research
researchProduct

Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer

2007

Interleukin-7-receptor-signaling plays a pivotal role in T-cell development and maintenance of T-cell memory. We studied IL-7Ralpha (CD127) expression in PBMCs obtained from patients with breast cancer and examined IL-7 receptor-mediated downstream effects defined by STAT5 phosphorylation (p-STAT5). Reduced numbers of IL-7Ralpha-positive cells were identified in CD4+ T-cells as well as in a CD8+ T-cell subset defined by CD8alpha/alpha homodimer expression in patients with breast cancer. PBMCs obtained from healthy donors (n = 19) and from patients with breast cancer (n = 19) exhibited constitutive p-STAT5 expression in the range of 0-6.4% in CD4+ T-cells and 0-4% in CD8+ T-cells. Stimulatio…

CD4-Positive T-LymphocytesCancer Researchmedicine.medical_specialtyT-Lymphocytesmedicine.medical_treatmentBreast NeoplasmsCD8-Positive T-LymphocytesPeripheral blood mononuclear cellchemistry.chemical_compoundImmune systemBreast cancerInternal medicineSTAT5 Transcription FactormedicineHumansPhosphorylationInterleukin-7 receptorSTAT5Receptors Interleukin-7biologybusiness.industryInterleukin-7Flow Cytometrymedicine.diseaseRecombinant ProteinsCytokineEndocrinologyOncologychemistryIonomycinLeukocytes Mononuclearbiology.proteinCytokinesFemalebusinessCD8Signal TransductionInternational Journal of Cancer
researchProduct

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injec…

2001

Dendritic cells (DCs) elicit potent anti-tumoral T-cell responses in vitro and in vivo. However, different types of DC have yet to be compared for their capacity to induce anti-tumor responses in vivo at different developmental stages. Herein, we correlated the efficiencies of different types of monocyte-derived DC as vaccines on the resulting anti-tumor immune responses in vivo. Immature and mature DCs were separately pulsed with a peptide derived from tyrosinase, MelanA/MART-1 or MAGE-1 and a recall antigen. Both DC populations were injected every 2 weeks in different lymph nodes of the same patient. Immune responses were monitored before, during and after vaccination. Mature DCs induced …

CD4-Positive T-LymphocytesCancer Researchmedicine.medical_treatmentT cellchemical and pharmacologic phenomenaCD8-Positive T-LymphocytesInterferon-gammaImmune systemAdjuvants ImmunologicAntigenAntigens NeoplasmHumansMedicineCytotoxic T cellAntigen-presenting cellMelanomaNeoplasm Stagingbusiness.industryDendritic CellsImmunotherapyDendritic cellNeoplasm Proteinsmedicine.anatomical_structureOncologyImmunologyImmunizationLymph NodesPeptidesbusinessMelanoma-Specific AntigensCD8T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct